Involvement of metformin and AMPK in the radioresponse and prognosis of luminal versus basal-like breast cancer treated with radiotherapy

@inproceedings{Zhang2014InvolvementOM,
  title={Involvement of metformin and AMPK in the radioresponse and prognosis of luminal versus basal-like breast cancer treated with radiotherapy},
  author={Yimin Zhang and Sarah J. Storr and Kerstie Johnson and Andrew R. Green and Emad A Rakha and Ian O. Ellis and David A L Morgan and Stewart G Martin},
  booktitle={Oncotarget},
  year={2014}
}
Metformin is under evaluation as a potential anticancer agent. Expression of total and phospho(Thr172)-adenosine monophosphate-activated kinase-α (AMPKα and pAMPKα(Thr172) respectively), a main metformin target, was examined in radiotherapy treated breast cancers and metformin's ability to modulate Trx system expression and breast cancer radiosensitivity evaluated in vitro. AMPKα and pAMPKα(Thr172) expression was assessed using a discovery (n=166) and validation cohort (n=609). Metformin's role… CONTINUE READING